Search

Displaying results 2311 - 2320 of 10000 in total
  1. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … It was rejected for approval for use in the United States.

  2. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

  3. Drug

    Pancrelipase lipase

    go.drugbank.com/drugs/DB13147
    ApprovedInvestigational

    [L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.

    Products: Formula C & E
  4. Drug

    Human interferon beta

    go.drugbank.com/drugs/DB14999
    ApprovedInvestigational

    Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. … [L12078] Interferon-beta has been used in the past in clinical studies with other coronaviruses due to its demonstrated activity against the virus causing Middle Eastern Respiratory Syndrome (MERS).

  5. Drug

    Lanreotide

    go.drugbank.com/drugs/DB06791
    ApprovedInvestigational

    It is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome

    Products: Mytolac 60 mg Injektionslösung in einer Fertigspritze, Mytolac 90 mg Injektionslösung in einer Fertigspritze
  6. Drug

    Tafamidis

    go.drugbank.com/drugs/DB11644
    ApprovedInvestigational

    [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]

  7. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen … [L53013] It was granted an Orphan Drug designation by the EMA.[A273833]

    Synonyms: EB 101, EB-101
  8. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627]. … in combination with other antivirals for all six genotypes of Hepatitis C [L852].

  9. Drug

    Labetalol

    go.drugbank.com/drugs/DB00598
    ApprovedInvestigational

    [L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]

    Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium Chloride
  10. Drug

    Gadoquatrane

    go.drugbank.com/drugs/DB33282
    Approved

    in the central nervous system and in the body. … [L63930] Bayer announced FDA approval of gadoquatrane on June 15, 2026, for use with MRI in adult and pediatric patients, including term neonates, to detect and visualize lesions with abnormal vascularity